Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
A series of novel matrix metalloproteinase inhibitors is described in which selectivity between MMP and 'sheddase' activity has been achieved and which demonstrate potent in vivo activity in models of arthritis and cancer.
Baxter
A D
AD
Celltech Chiroscience Ltd, Granta Park, Cambridge CB1 6GS, Abington, UK.
Bhogal
R
R
Bird
J
J
Keily
J F
JF
Manallack
D T
DT
Montana
J G
JG
Owen
D A
DA
Pitt
W R
WR
Watson
R J
RJ
Wills
R E
RE
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000188:drug therapy; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006877:Hydroxamic Acids / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D061965:Matrix Metalloproteinase Inhibitors; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; C100342:marimastat